# Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

> **NCT05835479** · PHASE2 · RECRUITING · sponsor: **Mundipharma Research Limited** · enrollment: 50 (estimated)

## Conditions studied

- Pneumocystis Pneumonia

## Interventions

- **DRUG:** Co-Trimoxazole
- **DRUG:** Rezafungin Acetate / Co Trimoxazole

## Key facts

- **NCT ID:** NCT05835479
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2025-05
- **Final completion:** 2025-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835479, "Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05835479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*